Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Debt (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Non-Current Debt history runs 12 years deep, the most recent figure standing at $36.1 million for Q1 2026.

• On a quarterly basis, Non-Current Debt rose 74.48% year-over-year to $36.1 million in Q1 2026; TTM through Mar 2026 was $36.1 million, a 74.48% increase from a year earlier, with the FY2025 full-year figure at $34.2 million, changed N/A from the prior year.
• Non-Current Debt improved to $36.1 million in Q1 2026 per VRDN's latest filing, from $34.2 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $36.1 million in Q1 2026 and bottomed at $4.6 million in Q2 2022.
• The 5-year median for Non-Current Debt is $20.0 million (2023), against an average of $16.4 million.
• Across the five-year window, Non-Current Debt soared 334.98% in 2023 and declined 29.36% in 2025, its largest moves.
• Year by year, Non-Current Debt stood at $4.6 million in 2022, then surged by 334.98% to $20.2 million in 2023, then climbed by 1.57% to $20.5 million in 2024, then soared by 66.86% to $34.2 million in 2025, then advanced by 5.4% to $36.1 million in 2026.
• Per Business Quant, the three latest VRDN Non-Current Debt figures stand at $36.1 million (Q1 2026), $34.2 million (Q4 2025), and $20.9 million (Q3 2025).